Global Amphotericin B Market Growth (Status and Outlook) 2025-2031

According to this study, the global Amphotericin B market size will reach US$ million by 2031.

Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses.

United States market for Amphotericin B is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Amphotericin B is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Amphotericin B is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Amphotericin B players cover Bristol-Myers Squibb, Matinas BioPharma, Nanox, Nanomerics, DNDi, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Amphotericin B Industry Forecast” looks at past sales and reviews total world Amphotericin B sales in 2024, providing a comprehensive analysis by region and market sector of projected Amphotericin B sales for 2025 through 2031. With Amphotericin B sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Amphotericin B industry.

This Insight Report provides a comprehensive analysis of the global Amphotericin B landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Amphotericin B portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Amphotericin B market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Amphotericin B and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Amphotericin B.

This report presents a comprehensive overview, market shares, and growth opportunities of Amphotericin B market by product type, application, key players and key regions and countries.

Segmentation by Type:
Static Drops
Atomization Inhalation
Local Lesion Injection
Other

Segmentation by Application:
Vaginitis
Candida Infection
Leishmaniasis
Kala-Azar
Cryptococcal Infection
Aspergillus Infection
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bristol-Myers Squibb
Matinas BioPharma
Nanox
Nanomerics
DNDi
Abzena
Bharat Serums
Jina Pharma
Astellas Pharma
Leadiant Biosciences
Kadmon Corporation (Eli Lilly and Company)
InterMune
Sterimax Inc
X-GEN Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver. Show more